NEW YORK (GenomeWeb News) – MyoKardia, a San Francisco-based drug startup, has been launched with $38 million in Series A financing from Third Rock Ventures.

The firm is taking a genetically targeted approach to drug development, using a proprietary drug discovery platform that combines advances in cardiovascular genomics and heart muscle biology research. According to the firm, its approach will "leverage resident expertise in sarcomere genetics, in vivo and in vitro disease models, next-generation biochemical and biophysical assay development, and medicinal chemistry."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.